Alopecia Areata: Clinical Trials

219 trials for Alopecia Areata, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

93 completed, 40 unknown, 33 recruiting, 17 terminated. 70 Phase 2, 41 Not applicable, 28 Phase 3, 24 Phase 4, 21 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 270Completed 31, Recruiting 10, Terminated 10, Unknown 8, Withdrawn 6, Active not recruiting 3, Not yet recruiting 2
Not applicable41Completed 20, Unknown 13, Not yet recruiting 2, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 328Completed 15, Recruiting 7, Active not recruiting 3, Terminated 2, Unknown 1
Phase 424Completed 12, Unknown 5, Not yet recruiting 4, Terminated 2, Recruiting 1
Phase 121Unknown 7, Completed 5, Recruiting 5, Active not recruiting 2, Terminated 1, Withdrawn 1
Early Phase 17Completed 4, Unknown 2, Active not recruiting 1

Follow Alopecia Areata: new trials by email Literature Review of Alopecia Areata trials Research Report on Alopecia Areata

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata
Calcipotriol, Triamcinolone Acetonide - Alopecia Areata		Phase 4Not yet recruitingHayat Abad Medical Complex, Peshawar602026-10-012026-09-21
The Role of Gut and Skin Microbiota in Alopecia Areata
Fecal Microbial Transplant Enema, Placebo - Alopecia Areata, Fecal Microbiota Transplantation (FMT)		Not applicableNot yet recruitingPolyclinic GrandMed302026-10-012026-07-15
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
VC005 tablets - Alopecia Areata		Phase 1RecruitingJiangsu vcare pharmaceutical technology co., LTD242026-09-222026-10-20
An Observational Study of Patients With Dermatologic Disease
Vitiligo, Atopic Dermatitis		Not yet recruitingTarget PharmaSolutions, Inc.20000002026-09-012026-09-10
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Upadacitinib, Placebo - Severe Alopecia Areata		Phase 3RecruitingAbbVie3002026-08-242026-10-27
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Drug: VC005 tablets, VC005 tablets, VC005 placebo tablets - Alopecia Areata		Phase 2RecruitingJiangsu vcare pharmaceutical technology co., LTD1202026-08-182026-08-27
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
ritlecitinib - Alopecia Areata		Active not recruitingPfizer12026-08-172026-10-16
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - Alopecia Areata		Phase 3RecruitingPfizer3362026-07-302026-10-26
UV-Trichoscopic Red Fluorescence in Alopecia Areata
Triamcinolone Acetonide - Alopecia Areata		RecruitingIstanbul Training and Research Hospital402026-07-012026-09-11
New Topical Treatment in Patchy Alopecia Areata
topical metformin 30% ointment, Topical Simvastatin 2% ointment, Topical betamethasone valerate 0.1% ointment - Alopecia Areata		Not applicableNot yet recruitingSohag University602026-06-282026-07-10
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Deuruxolitinib, Placebo - Alopecia Areata		Phase 3RecruitingSun Pharma Japan Limited782026-06-192026-10-30
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
Alopecia Areata(AA), Alopecia Areata		RecruitingIstanbul Training and Research Hospital1562026-06-012026-07-30
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
placebo, Baricitinib tablets, IBI3013 - Healthy, Active Non-segmental Vitiligo		Phase 1RecruitingInnovent Biologics (Suzhou) Co. Ltd.1602026-04-182026-04-28
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
LY4005130, Placebo - Alopecia Areata		Phase 2RecruitingEli Lilly and Company652026-04-142026-10-28
Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata
Microvascular Imaging, Biochemical Biomarker Analysis, Trichoscopic Imaging - Alopecia Areata, Alopecia Areata(AA)		Enrolling by invitationIstanbul Training and Research Hospital902026-04-012026-03-30
Topical Methotrexate vs Minoxidil for Localized Alopecia Areata
Methotrexate 1% Topical Gel, Minoxidil 5% Topical Spray - Alopecia Areata		Phase 4Not yet recruitingJinnah Postgraduate Medical Centre2682026-03-152026-03-10
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
Tofacitinib, Methotrexate - Alopecia Areata, Alopecia Totalis (AT)		Phase 4Not yet recruitingHayat Abad Medical Complex, Peshawar782026-02-152026-02-12
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Abrocitinib - Atopic Dermatitis, Alopecia Areata		Phase 2RecruitingIcahn School of Medicine at Mount Sinai562026-01-122026-10-16
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
Conventional Systemic Therapies, Biologic Therapies - Psoriasis, Atopic Dermatitis		Not yet recruitingFondazione ISIDE200002026-01-012026-01-15
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Ritlecitinib - Alopecia Areata		CompletedPfizer3002025-12-222026-08-10

Showing 20 of 219. Sign in to see all of them.

Narrower conditions

Alopecia (36)  ·  Alopecia universalis (29)  ·  Dermatitis, Atopic (16)  ·  Vitiligo (16)  ·  Psoriasis (15)  ·  Hidradenitis Suppurativa (11)  ·  Hair Diseases (7)  ·  Autoimmune Diseases (6)  ·  Colitis, Ulcerative (5)  ·  Crohn Disease (5)  ·  Lupus Erythematosus, Systemic (5)  ·  Down Syndrome (4)  ·  Multiple Sclerosis (4)  ·  Skin Diseases (4)

Broader conditions

Skin and Connective Tissue Diseases (219)  ·  Hypotrichosis (217)  ·  Skin Diseases (215)  ·  Hair Diseases (212)  ·  Alopecia (183)  ·  Pathological Conditions, Signs and Symptoms (42)  ·  Pathological Conditions, Anatomical (36)  ·  Immune System Diseases (24)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (19)  ·  Genetic Diseases, Inborn (18)  ·  Hypersensitivity, Immediate (17)  ·  Skin Diseases, Eczematous (17)  ·  Skin Diseases, Papulosquamous (17)  ·  Dermatitis (16)  ·  Hypersensitivity (16)

Interventions

Triamcinolone Acetonide (16)  ·  tofacitinib (9)  ·  baricitinib (7)  ·  Methotrexate (5)  ·  upadacitinib (5)  ·  PF-06651600 (4)  ·  Saline Solution (4)  ·  ruxolitinib (4)  ·  Abatacept (3)  ·  Bimatoprost (3)  ·  Latanoprost (3)  ·  Ointments (3)  ·  Solutions (3)  ·  Triamcinolone (3)  ·  calcipotriene (3)

Sponsors

Pfizer (17)  ·  Assiut University (9)  ·  University of Minnesota (7)  ·  Concert Pharmaceuticals (6)  ·  Icahn School of Medicine at Mount Sinai (6)  ·  Sohag University (6)  ·  AbbVie (5)  ·  Columbia University (5)  ·  Al-Azhar University (4)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (4)  ·  Aclaris Therapeutics, Inc. (3)  ·  Benha University (3)  ·  Cairo University (3)  ·  Eli Lilly and Company (3)  ·  Hordinsky, Maria K., MD (3)

Countries

United States (98)  ·  Egypt (31)  ·  Canada (28)  ·  China (24)  ·  France (19)  ·  Japan (18)  ·  Australia (15)  ·  United Kingdom (15)  ·  Spain (14)  ·  Poland (13)  ·  Germany (11)  ·  South Korea (11)  ·  Czechia (8)  ·  Taiwan (8)  ·  Italy (7)

Top investigators

Maria Hordinsky, MD (8)  ·  Julian Mackay-Wiggan, MD, MS (6)  ·  Emma Guttman, MD, PhD (3)  ·  Andrew McGovern, MD (2)  ·  Brett King, MD, PhD (2)  ·  Emma Guttman-Yassky, MD, PhD (2)  ·  Houman Hemmati, MD (2)  ·  Laura Dalfonso (2)  ·  Madeleine Duvic, MD (2)  ·  Maria K Hordinsky, MD (2)  ·  Marna Ericson, Ph D (2)  ·  Olfat G Shaker, MD (2)

Results publications

PMID 38263353, PMID 41917311, PMID 42481842, PMID 25896390, PMID 27699252, PMID 28300084, PMID 28619556, PMID 29273099, PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37917289, PMID 37991697, PMID 38904749, PMID 39962358, PMID 40214720, PMID 42823604, PMID 42825995, PMID 14582678, PMID 16417220, PMID 17236136, PMID 17637820, PMID 18329131, PMID 18489053, PMID 19620039, PMID 20115945, PMID 20115946, PMID 21199096, PMID 21712909, PMID 21899919, PMID 22233865, PMID 22512484, PMID 22524397, PMID 22833322, PMID 24202232, PMID 24226568, PMID 24237476, PMID 24872229, PMID 24940651, PMID 25315746, PMID 25601618, PMID 25676427, PMID 25765294, PMID 26183987, PMID 27699253, PMID 27816293, PMID 28139263, PMID 28635045

NIH funding

2023 (3), 2025 (3), 2016 (1), 2017 (1), 2018 (1), R33AR077495 (1), R61AR084210 (1)